

Thursday 18 January 2018 – 12:30 – 14:30

Light lunch and refreshments will be served before the event at 12:00-12:30

**Maison de la Paix (A1B Auditorium Ivan Pictet)
Chemin Eugène-Rigot 2, 1202 Geneva**

“Delivering on the SDGs: focus on industry’s actions in the fight against AMR”

Moderated by Dr. Ilona Kickbusch, Graduate Institute of International and Development Studies in Geneva

Event co-hosted by the AMR Industry Alliance and SustainAbility

Introduction (5 minutes)	<ul style="list-style-type: none"> Mr. Thomas Cueni, Director General, IFPMA, Chair, AMR Industry Alliance
Keynote speaker (10 minutes)	<ul style="list-style-type: none"> Dr. Ranieri Guerra, Assistant Director-General for Strategic Initiatives, World Health Organization
Key findings from the progress report (15 minutes)	<ul style="list-style-type: none"> Mrs. Denise Delaney, Director, Sustainability
Panel 1: Findings and good practices from the 4 commitments areas of the AMR Industry Declaration (45 minutes)	<ul style="list-style-type: none"> Mr. Gary M Cohen, Executive Vice President, Global Health and President, BD Foundation Dr. Sanjay Kakkar MD, MSc, MPH, CEO, Peptilogics, Inc. Dr. Bruce Altevogt, Senior Director of Science Policy and Science Advocacy, Pfizer Dr. Denis Broun, Global Director for access and public affairs, Cipla

Panel 2:

Setting targets for the future and identifying potential collaborations with the private sector

(45 minutes)

- Mr. Marc Sprenger, Director of the AMR Secretariat, World Health Organization
 - Mrs. Martha Gyansa-Lutterodt, Director of Pharmaceutical Services and Chief Pharmacist of Ghana
 - Mr. Thomas Cueni, Director General, IFPMA, Chair, AMR Industry Alliance
 - Dr. Manica Balasegaram, Director, Global Antibiotic Research & Development (GARDP)
 - Dr. Catharina Boehme, CEO, Foundation for Innovative New Diagnostics (FIND)
-



Dr Ranieri Guerra

WHO Assistant Director-General for Strategic Initiatives

Dr. Ranieri Guerra has been appointed Assistant Director General for Special Initiatives. A physician from Italy, he has more than 30 years of public health experience. Since 2014, he has served as Director General for Preventive Health and Chief Medical Officer of the Italian Ministry of Health. Additional roles include serving as Scientific Attaché for the Embassy of Italy in Washington, DC, Director of the WHO Collaborating Centre and Director of the Office of External Relations at the President’s Cabinet at the Istituto Superiore di Sanità, the national research organization of the Italian Ministry of Health, and Medical Director of the United Nations Relief and Works Agency (UNRWA). He has published extensively on humanitarian and emergency operations and health reform in developing and transitional countries. He also has worked with several multilateral organizations and the Italian Ministry of Foreign Affairs in these settings.



Mr. Thomas Cueni

Director General, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Chair of the AMR Industry Alliance

Thomas B. Cueni is Director General of IFPMA since 1 February 2017. Prior to joining IFPMA he was Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland. For many years Thomas Cueni has been involved in the work of the European Federation of Pharmaceutical Industries and Associations, EFPIA, where he most recently served as Vice-Chair of the European Markets Committee and association representative on the Board. He represented the industry on the EU High Level Pharmaceutical Forum, was Chairman of EFPIA’s Economic and Social Policy Committee and Chairman of the EFPIA Task Force on the EU Commission’s Pharmaceutical Sector Inquiry. Thomas Cueni also represented Interpharma, which he successfully transformed from the association of Swiss Rx companies to the association of pharmaceutical research companies in Switzerland, on the Council of IFPMA. Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”, and he served as a Swiss career diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basle, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).



Mrs. Denise Delaney

Director, SustainAbility

Based in London, Denise leads strategy and stakeholder engagement projects and our work on health with the pharmaceutical industry. She is expert in the design and execution of stakeholder engagement strategy. Denise also leads the European activities of our Engaging Stakeholders Network - advising our clients on integration, transparency and reporting. Relevant project experience includes AstraZeneca, GlaxoSmithKline, IFPMA, Novartis and Novo Nordisk. Her work with the industry spans materiality assessments, Access to Medicine Index (ATMI) performance assessments and stakeholder engagement strategy. She co-authored [Orchestrating Change: Catalyzing the Next Generation of Multi-Stakeholder Collaboration for Sustainability](#). Previously, Denise worked with a London-based consultancy in public stakeholder engagement and consultation. Denise has also worked with national and global NGOs as well as UN agencies in Latin America and India. Denise holds a BA in Social Anthropology from Harvard College and MSc in Forced Migration from Oxford University.



Mr. Gary M Cohen

Executive Vice President, Global Health and President, BD Foundation

Gary Cohen is the Executive Vice President, Global Health and President, BD Foundation at BD (Becton, Dickinson & Co). Mr. Cohen is also a board director of the Perrigo Company, CDC Foundation and UNICEF USA, board co-chair of GBCHealth, and board chair/founder of *Together for Girls*. He previously served on the UN Commission on Life Saving Commodities for Women and Children and presently serves on the Scientific Advisory Board of Grand Challenges Canada. Mr. Cohen and BD engage in extensive cross-sector collaboration to address unmet health needs globally, working with international agencies, governments and non-government organizations, focused on specific health goals such strengthening clinical and laboratory practices, safely immunizing children, addressing infectious and non-communicable diseases, reducing maternal and newborn mortality, combating antimicrobial resistance and improving safety for health workers and patients. He frequently serves as an expert speaker and advocate on advancing health and human rights, in various venues including the United Nations, Vatican, World Bank, World Health Assembly, U.S. Department of State and World Economic Forum-Davos. He has been honored for his humanitarian work by numerous organizations. Mr. Cohen holds B.A. and an M.B.A. degrees from Rutgers University and previously served on the university's board of trustees. In 2016 he was named a Rutgers 250 Fellow in association with the university's 250th anniversary.



Dr. Sanjay Kakkar

MD, MSc, MPH, CEO, Peptilogics, Inc.

Sanjay is a healthcare entrepreneur with over 20 years of experience in multinational corporations and high growth enterprises. He has a strong track record of building innovative companies in healthcare industries and development of novel technologies for the improvement of human health. Sanjay was formerly CEO of Armetheon, Inc., a biopharmaceutical company focused on novel therapeutics for cardiovascular diseases with assets in Phase 2 and Phase 3 development. Sanjay was the Chairman and Founder of Jai Health a cardiovascular-focused personalized healthcare company. He is also the former CEO and Co-Founder of Trigen, a biopharmaceutical company that he built from a virtual company based in an academic research institute to become a leading biotech company with a pipeline of early-to-mid clinical-stage products and a broad portfolio of preclinical candidates. During his tenure as CEO, he has led companies through multiple financing rounds and attained key value-generating milestones including completion of clinical trials, significant regulatory agreements and execution of licensing agreements and mergers. In 2004 he was recognized with the LBN Biotech Entrepreneur of the Year Award. Sanjay is a medical graduate from King's College, University of London, holds a Master's degree in healthcare management from Harvard University and a Master's in preventive cardiology from Imperial College.



Dr. Denis Broun

Permanent observer in Geneva of the Partnership for Population and Development with Ambassador rank and adviser to the Chairman and the CEO of CIPLA

Denis Broun is a French citizen, born in Paris in 1955. He is married and has four children. Denis is a doctor of medicine from Paris University with a specialization in infectious diseases, parasitology and epidemiology. He also holds a diploma from the Paris Institute of Political Sciences and a masters in biomathematics. Denis Broun has worked in the field of international health for the past thirty years, first as a health economist with a French engineering company, then as senior health specialist in the World Bank, where he was in charge of the pharmaceutical sector from 1992 to 1996. He then became head of the health section of UNICEF until 1998, when he joined the World Health Organization in Geneva, first as programme manager for the control of tropical diseases, and then director of resource mobilization. Denis Broun became European director of the American consulting firm “Management Sciences for Health” from 2000 to 2005 and in 2005 joined UNAIDS, first as country coordinator in India (2005-2008), then director of partnerships and finally regional director for Europe and Central Asia, based in Moscow. In 2011, he was selected as executive director of UNITAID, a position he held until March 2014. Denis is currently permanent observer in Geneva of the Partnership for Population and Development with Ambassador rank and serves as an adviser to the Chairman and the CEO of CIPLA, a leading Indian generic manufacturer. He also serves on the Board of several companies. In addition to his native French, Dr. Broun speaks English, Russian, Spanish and some Hindi.



Dr. Bruce Altevogt

Senior Director of Science Policy and Science Advocacy, Pfizer

Bruce Altevogt is a Director of Science Policy and Science Advocacy at Pfizer Inc.’s Policy Center of Excellence, within Global Policy and International Public Affairs. In this role Dr. Altevogt is responsible for managing policy issues in support of Pfizer’s research & development enterprise and global health security initiatives, including anti-microbial resistance and vaccine preparedness. Prior to joining Pfizer Inc., Dr. Altevogt spent over 11 years as a senior program officer on the Board on Health Sciences Policy at the Institute of Medicine (IOM). While at the IOM, he worked on policy issues related to basic and translational research, drug discovery and development, and preparedness for catastrophic events. He oversaw the publication of over 50 IOM reports and directed multiple IOM studies. In his capacity at the IOM he served as director of the Forum on Medical and Public Health Preparedness for Catastrophic Events and the Forum on Neuroscience and Nervous System Disorders Forum. Dr. Altevogt received his doctorate from Harvard University’s Program in Neuroscience. Following more than 10 years of research, Dr. Altevogt joined The National Academies as a science and technology policy fellow with the Christine Mirzayan Science & Technology Policy Graduate Fellowship Program. He received his B.A. from the University of Virginia in Charlottesville, where he majored in Biology and minored in South Asian Studies. He is a published author of multiple scientific articles.



Dr Manica Balasegaram

Director, GARDP, DNDi

Dr Manica Balasegaram, who is a medical doctor by training, started his career in internal and emergency medicine in the UK and in Australia, then joined Médecins sans Frontières as a field physician in Sub-Saharan Africa and Southern Asia. He was later appointed Head of the MSF Manson Unit, before initially joining DNDi as Head of Leishmaniasis – a position he left four years ago to become the MSF Access Campaign’s Executive Director. His experience spans clinical and public health practice in neglected and infectious diseases, clinical trials and drug development, international work on health policy and access to medicines and involvement in a variety of expert technical committees. He rejoined DNDi in June 2016 as Director of the Global Antibiotic Research & Development Partnership, a joint DNDi-WHO initiative.



Dr. Martha Gyansa-Lutterodt

Director of Pharmaceutical Services and Chief Pharmacist- Ghana

Martha Gyansa-Lutterodt is the Director of Pharmaceutical Services and also the Chief Pharmacist of Ghana. Martha is a product of Kwame Nkrumah University of Science and Technology, Ghana, Leeds University, United Kingdom and GIMPA’s School of Governance and Leadership. She serves on several national and international boards including Lancet Commissioner on Essential Medicines and also as an Expert member of World Health Organisation Expert Committee on Medicines Policies and Management, WHO, Geneva. She has served on several WHO and World Trade Organisation, West African Health Organisation consultations on Trade Related International Property Rights as well as medicines policies. She has several publications on various topics like TRIPS, DOHA and Access to medicines, policy options for Ghana, Antibiotic Resistance in Ghana by Lancet Infectious Diseases, Essential Medicines in Universal Health Coverage among others. She is also the chair for Ghana chapter of International Society for Pharmacoeconomics and Outcomes Research (ISPOR). She has coordinated several assessments of the pharmaceutical sector in Ghana with meaningful contributions to the health sector dialogue. Mrs Gyansa-Lutterodt is a Fellow of West African Post-graduate College of Pharmacists and a Foundation Fellow of Ghana College of Pharmacists. Martha is the current chair for Ghana’s Antimicrobial Resistance Working group that responded to the Global Action Plan on antimicrobial resistance with a country working mechanism. She has recently been appointed to the United Nations Ad Hoc Committee on Antimicrobial Resistance. She has been recognized and awarded recently for her contribution to Health and Pharmacy development and practice in Ghana by the Ghana Women of Excellence Awards’.



Dr Marc Sprenger

Director, Antimicrobial Resistance Secretariat, WHO

Dr Marc Sprenger is Director of the World Health Organization (WHO) secretariat for antimicrobial resistance. Marc and this secretariat focus on coordination of an Organization-wide approach to antimicrobial resistance, working with WHO programmes carrying out technical activities required for the implementation of the global action plan on antimicrobial resistance. The coordinating secretariat was established following adoption of the global action plan on antimicrobial resistance by the World Health Assembly in May 2015. The plan sets out five strategic objectives:

- improve awareness and understanding of antimicrobial resistance;
- strengthen knowledge through surveillance and research;
- reduce the incidence of infection;
- optimize the use of antimicrobial medicines; and

- develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions.

Prior to joining WHO, from 2010 Dr Sprenger was Director of the European Centre for Disease Prevention and Control (ECDC) in Stockholm, Sweden. Before that he was Director-General of the National Institute for Public Health and the Environment (RIVM) in Bilthoven, the Netherlands. A national of the Netherlands, Marc is a medical doctor, medical microbiology specialist and has a PhD in epidemiology.



Dr. Catharina Boehme

CEO of FIND

Dr. Catharina Boehme is the Chief Executive Officer of FIND, an international non-profit organization headquartered in Geneva, Switzerland that drives the development and delivery of diagnostic tests for diseases of poverty. Under Catharina's leadership, 10 new diagnostic tools have been introduced in resource poor settings over the last 3 years, for sleeping sickness, Malaria and tuberculosis. She has expanded FIND's scope to include outbreak preparedness, hepatitis elimination and Antimicrobial Resistance and is passionate about closing the massive diagnostic gap in tuberculosis, the leading global infectious disease killer. Catharina holds a MD from Ludwig Maximilians University in Munich and Heidelberg University, Germany, as well as diplomas in Public Health and Management. She is the Chair of the New Diagnostics Working Group of the Stop TB Partnership and serves on several Public Health Advisory Committees (WHO TB STAG; EU Horizon 2020 Dx; Australian Innovation Exchange Programme). She has more than 100 publications. Prior to joining FIND in 2005 with a focus on clinical trials and laboratory strengthening, she worked for the Department of Infectious and Tropical Diseases in Munich and established a TB diagnostic research unit at Mbeya Medical Research Program in Tanzania.



Dr. Ilona Kickbusch

Director of the Global Health Centre and Adjunct Professor, Interdisciplinary Programmes, Graduate Institute of International and Development Studies in Geneva

Ilona Kickbusch is the Director of the Global Health Centre and adjunct professor at the Graduate Institute of International and Development Studies in Geneva. She has been deeply involved in the development of the Health 2020 European health policy framework. She was a member of the independent Ebola interim assessment panel of the WHO. She has recently been awarded the Cross of the Order of Merit of the Federal Republic of Germany (Bundesverdienstkreuz) in recognition of her invaluable contributions to innovation in governance for global health and global health diplomacy. She is a senior advisor to the Regional Directors of the WHO Regional Offices for Europe and the Eastern Mediterranean and has advised many countries on their global health strategies. In Switzerland she serves on the executive board of the Careum Foundation and on the expert panel advising the Federal Councillor responsible for health. She has contributed to innovation in health in many ways throughout her career and has a strong commitment to the empowerment of women. She has worked with the WHO at various levels and in academia as professor at Yale University. She has published widely and has received many prizes for her work.



About the AMR Industry Alliance

The life sciences industry has been a longstanding partner in finding sustainable solutions to the problem. In an unprecedented effort, over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and associations, signed the AMR Industry Declaration at the World Economic Forum in Davos in 2016, followed by the adoption of a Roadmap by a number of companies at the UN High-Level Meeting on later that year. The [AMR Industry Alliance](#), launched in May 2017, sets out a common set of principles for global action that focus on reducing the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics. The Alliance has developed a reporting mechanism with the support of [SustainAbility](#) in order to ensure that the signatories deliver on their commitments to take stock of activities undertaken to date, and inform future targets.